US EditionZepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
- A U.S.-based clinical trial comparing the two drugs showed that participants treated with Eli Lilly's Zepbound experienced almost 50% greater weight reduction over 72 weeks than those who received Novo Nordisk's Wegovy.
- The trial involved 751 overweight or obese adults with at least one related health problem and no diabetes, comparing tirzepatide targeting GLP-1 and GIP to semaglutide targeting GLP-1 alone.
- Zepbound users lost about 50 pounds and 18.4 centimeters in waist circumference, while Wegovy users lost 33 pounds and 13 centimeters, with mostly mild gastrointestinal side effects reported in both groups.
- Nearly one-third of participants taking Zepbound experienced a weight reduction of 25% or more, which was double the proportion seen in those using Wegovy, and Dr. Louis Aronne referred to tirzepatide as demonstrating superior effectiveness in a "drag race of efficacy."
- The findings may influence prescribing decisions as both drugs remain important treatments, though CVS Health will favor Wegovy on its formulary starting July 1 due to its approval for reducing heart risks.
216 Articles
216 Articles
This GLP-1 Is the Most Effective for Weight Loss, Study Says
A new study says that people who use tirzepatide lose more weight than people who use semaglutide Getty Stock image of a woman weighing herself.Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications The study was funded by Eli Lilly, the pharmaceutical company that manufactures tirzepatide, so "take that with a grain of salt," one expert saidTirzepatide, which reduces appetite and improves h…
PODCAST: CFRA's House Calls for Sun. May 11th, 2025
Eli Lilly has plastered a 'fat tax' on the Canadian market for their weight loss drug. Dr. Yoni Freedhoff joins the program with his reaction. Then, Dr. Dworkin opens the phone lines and reads your texts.
Coverage Details
Bias Distribution
- 60% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
